Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/FTD.0000000000000838 http://scihub22266oqcxt.onion/10.1097/FTD.0000000000000838 33230045!7808275!33230045     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Drug+Monit 2021 ; 43 (1): 131-135 Nephropedia Template TP {{tp|p=33230045|t=2021. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients |pdf=|usr=}}{{33230045}} gab.com Text Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients JO: Ther Drug Monit http://www.kidney.de/pget.php?&tw=1&pmid=33230045 #FOAvip BACKGROUND: Although the efficacy of lopinavir/ritonavir has not been proven, it has been proposed as an off-label treatment for COVID-19. Previously, it has been reported that the plasma concentrations of lopinavir significantly increase in inflammatory settings. As COVID-19 may be associated with major inflammation, assessing the plasma concentrations and safety of lopinavir in COVID-19 patients is essential. METHODS: Real-world COVID-19 data based on a retrospective study. RESULTS: Among the 31 COVID-19 patients treated with lopinavir/ritonavir between March 18, 2020 and April 1, 2020, higher lopinavir plasma concentrations were observed, which increased by 4.6-fold (interquartile range: 3.6-6.2), compared with the average plasma concentrations in HIV. Lopinavir concentrations in all except one patient were above the upper limit of the concentration range of HIV treatment. Approximately one to 5 patients prematurely stopped treatment mainly because of an ADR related to hepatic or gastrointestinal disorders. CONCLUSIONS: Lopinavir plasma concentrations in patients with moderate-to-severe COVID-19 were higher than expected, and they were associated with the occurrence of hepatic or gastrointestinal adverse drug reactions. However, a high plasma concentration may be required for in vivo antiviral activity against SARS-CoV-2, as suggested by previous studies. Therefore, in the absence of adverse drug reaction, lopinavir dosage should not be reduced. Caution is essential because off-label use can be associated with a new drug safety profile. Twit Text FOAVip Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients ????Ther Drug Monit http://www.kidney.de/pget.php?&tw=1&pmid=33230045 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33230045 #FOAvip English Wikipedia <ref>{{Cite pmid|33230045}}</ref> Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients #MMPMID33230045 Chouchana L; Boujaafar S; Gana I; Preta LH; Regard L; Legendre P; Azoulay C; Canoui E; Zerbit J; Carlier N; Terrier B; Kerneis S; Batista R; Treluyer JM; Zheng Y; Benaboud S Ther Drug Monit 2021[Feb]; 43 (1): 131-135 PMID33230045show ga BACKGROUND: Although the efficacy of lopinavir/ritonavir has not been proven, it has been proposed as an off-label treatment for COVID-19. Previously, it has been reported that the plasma concentrations of lopinavir significantly increase in inflammatory settings. As COVID-19 may be associated with major inflammation, assessing the plasma concentrations and safety of lopinavir in COVID-19 patients is essential. METHODS: Real-world COVID-19 data based on a retrospective study. RESULTS: Among the 31 COVID-19 patients treated with lopinavir/ritonavir between March 18, 2020 and April 1, 2020, higher lopinavir plasma concentrations were observed, which increased by 4.6-fold (interquartile range: 3.6-6.2), compared with the average plasma concentrations in HIV. Lopinavir concentrations in all except one patient were above the upper limit of the concentration range of HIV treatment. Approximately one to 5 patients prematurely stopped treatment mainly because of an ADR related to hepatic or gastrointestinal disorders. CONCLUSIONS: Lopinavir plasma concentrations in patients with moderate-to-severe COVID-19 were higher than expected, and they were associated with the occurrence of hepatic or gastrointestinal adverse drug reactions. However, a high plasma concentration may be required for in vivo antiviral activity against SARS-CoV-2, as suggested by previous studies. Therefore, in the absence of adverse drug reaction, lopinavir dosage should not be reduced. Caution is essential because off-label use can be associated with a new drug safety profile. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Antiviral Agents/administration & dosage/adverse effects/*blood/*therapeutic use[MESH] |Comorbidity[MESH] |Drug Combinations[MESH] |Female[MESH] |Humans[MESH] |Lopinavir/administration & dosage/adverse effects/*blood/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Ritonavir/administration & dosage/adverse effects/*blood/*therapeutic use[MESH] |SARS-CoV-2[MESH]Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Pa(epmc).pdf DeepDyve Pubget Overpricing